AstraZeneca officer granted shares under incentive plan

AstraZeneca PLC officer Mani Sharma reported a small share-based compensation award.

Rhea-AI Filing Summary

AstraZeneca PLC officer Mani Sharma reported a small share-based compensation award. On July 6, 2026, Sharma acquired 2 Ordinary Shares in a grant/award transaction at $190.43 per share, linked to the company’s Share Incentive Plan at GBP142.492 per share. The price was converted using a GBP1.0000 to $1.3364 rate published on July 2, 2026. After this award, Sharma directly holds 19,265.4659 Ordinary Shares, reflecting a routine compensation-related acquisition rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 2 shares

Grant/Award 1 txn

Insider Sharma Mani

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	2	$190.43	$380.86

Holdings After Transaction: Ordinary Shares — 19,265.4659 shares (Direct)

Footnotes (1)

1. F1. Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP142.492, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3364 on July 2, 2026 as published by the Board of Governors of the Federal Reserve System.

Key Figures

Shares granted: 2 Ordinary Shares Grant price (USD): $190.43 per share Grant price (GBP): GBP142.492 per share +2 more

5 metrics

Shares granted 2 Ordinary Shares Grant/award acquisition on July 6, 2026

Grant price (USD) $190.43 per share Recorded value for the 2-share award

Grant price (GBP) GBP142.492 per share Share Incentive Plan price before FX conversion

FX conversion rate GBP1.0000 to $1.3364 Rate published July 2, 2026 for conversion

Shares held after 19,265.4659 Ordinary Shares Direct holdings following the award

Key Terms

Share Incentive Plan, grant/award acquisition, Ordinary Shares, conversion rate

4 terms

Share Incentive Plan financial

"Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP142.492"

A share incentive plan is a company program that gives employees or directors the chance to receive or buy company shares, often after staying with the firm or meeting performance goals. It matters to investors because it’s like giving workers a slice of the company pie to boost performance and loyalty, but issuing those slices can reduce each existing owner’s portion and change metrics such as earnings per share and share count.

grant/award acquisition financial

"transaction_action": "grant/award acquisition","transaction_code_description": "Grant, award, or other acquisition""

Ordinary Shares financial

""security_title": "Ordinary Shares","transaction_date": "2026-07-06T00:00:00.000Z""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

conversion rate financial

"converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3364"

Conversion rate is the proportion of items, people or contracts that take a desired action out of the total possible — for example the share of website visitors who make a purchase, or the number of convertible bonds that are exchanged for shares. Investors care because it measures how effectively a business or financial instrument turns opportunity into real outcomes, like sales or share issuance, which directly affects revenue, cash flow and ownership dilution.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AstraZeneca (AZN) report for Mani Sharma?

AstraZeneca reported that officer Mani Sharma received a grant of 2 Ordinary Shares under the company’s Share Incentive Plan. This is a compensation-related acquisition, not an open-market trade, and modestly increases Sharma’s direct holdings.

At what price were Mani Sharma’s new AstraZeneca (AZN) shares recorded?

The awarded 2 Ordinary Shares for Mani Sharma were recorded at $190.43 per share. This reflects a Share Incentive Plan price of GBP142.492, converted using a rate of GBP1.0000 to $1.3364 set on July 2, 2026.

How many AstraZeneca (AZN) shares does Mani Sharma hold after this grant?

Following the grant, Mani Sharma directly holds 19,265.4659 Ordinary Shares of AstraZeneca PLC. This updated figure includes the 2-share incentive award reported in the latest Form 4 and shows Sharma’s total direct equity position.

Was Mani Sharma’s AstraZeneca (AZN) transaction a market buy or a compensation award?

The transaction was a compensation award, coded as a grant/award acquisition. It represents shares received through AstraZeneca’s Share Incentive Plan rather than shares bought or sold in the open market, indicating routine equity-based compensation.

What currency conversion was used for Mani Sharma’s AstraZeneca (AZN) share grant?

The share grant price of GBP142.492 was converted to $190.43 using a rate of GBP1.0000 to $1.3364. This conversion rate was published by the Board of Governors of the Federal Reserve System on July 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sharma Mani

(Last) (First) (Middle)

C/O ASTRAZENECA PLC 1 FRANCIS

CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE CB2 0AA

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASTRAZENECA PLC [ AZN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/06/2026		A		2	A	$190.43(1)	19,265.4659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP142.492, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3364 on July 2, 2026 as published by the Board of Governors of the Federal Reserve System.

Remarks:

SVP, Group Controller and Head of Global Finance Services

	/s/ Mani Sharma	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)